Schnitt S J, Connolly J L, Tavassoli F A, Fechner R E, Kempson R L, Gelman R, Page D L
Department of Pathology, Beth Israel Hospital, Boston, Massachusetts 02215.
Am J Surg Pathol. 1992 Dec;16(12):1133-43. doi: 10.1097/00000478-199212000-00001.
Although the categorization of proliferative breast lesions provides valuable information regarding subsequent risk of breast cancer, the ability of pathologists to classify such lesions in a reproducible fashion has not been adequately evaluated. To assess further interobserver reproducibility in the categorization of proliferative breast lesions, six pathologists each reviewed 24 proliferative ductal lesions and classified them as either usual hyperplasia (H), atypical hyperplasia (AH), or carcinoma in situ (CIS). Before evaluation of the study slides, all the participants were instructed to use the diagnostic criteria of Page and co-workers and were provided with both a written summary of these criteria and a set of teaching slides with representative examples of each type of lesion. Complete agreement among all six pathologists was seen in 14 cases (58%); five or more agreed in 17 cases (71%); and four or more arrived at the same diagnosis in 22 cases (92%). No pathologist consistently rendered more "benign" or "malignant" diagnoses than any other. After assigning numerical values for each diagnostic category (H = 1, AH = 2, CIS = 3), the scores for the group of 24 cases did not differ significantly by pathologist (p = 0.68; average score range, 1.7-2.0). Our results indicate that with the use of standardized criteria, interobserver concordance in the diagnosis of proliferative ductal breast lesions can be obtained in the majority of cases.
尽管乳腺增生性病变的分类为后续乳腺癌风险提供了有价值的信息,但病理学家以可重复方式对这类病变进行分类的能力尚未得到充分评估。为进一步评估乳腺增生性病变分类中观察者间的可重复性,六位病理学家每人审阅了24例增生性导管病变,并将其分类为普通增生(H)、非典型增生(AH)或原位癌(CIS)。在评估研究切片之前,所有参与者均被要求使用佩奇及其同事的诊断标准,并获得了这些标准的书面总结以及一组包含每种病变类型代表性实例的教学幻灯片。六位病理学家在14例病例(58%)中达成完全一致;17例病例(71%)中有五位或更多人意见一致;22例病例(92%)中有四位或更多人得出相同诊断。没有病理学家一贯做出比其他病理学家更多“良性”或“恶性”的诊断。在为每个诊断类别赋予数值(H = 1,AH = 2,CIS = 3)后,24例病例组的得分在不同病理学家之间无显著差异(p = 0.68;平均得分范围为1.7 - 2.0)。我们的结果表明,使用标准化标准时,在大多数病例中可获得乳腺增生性导管病变诊断的观察者间一致性。